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Background. Endothelial dysfunction (ED), low-grade inflammation (LGI) and oxidative stress (OxS) may be involved
in the pathobiology of depression. Previous studies on the association of these processes in depression have yielded
contradictory results. We therefore investigated comprehensively, in a population-based cohort study, the association
between ED, LGI and OxS on the one hand and depressive symptoms on the other.
Method. We used data from the Hoorn Study and determined biomarkers of ED [flow-mediated dilatation (FMD),
von Willebrand factor, soluble intercellular adhesion molecule 1 (sICAM-1), soluble vascular cell adhesion molecule 1,
soluble thrombomodulin and soluble endothelial selectin], LGI [C-reactive protein, tumour necrosis factor-α, interleukin 6,
interleukin 8, serum amyloid A, myeloperoxidase (MPO) and sICAM-1] and OxS (oxidized low density lipoprotein
and MPO). Depressive symptoms were quantified by the Center for Epidemiologic Studies Depression Scale (CES-D)
questionnaire (n=493; age 68 years; 49.9% female). Regression analyses were performed with the use of biomarker
Z scores. Adjustments were made for age, sex and glucose metabolism status (cohort stratification variables) and
prior cardiovascular disease, hypertension, waist-to-hip ratio, cholesterol levels, education level, physical activity,
dietary habits, and the use of antihypertensive and/or lipid-lowering medication and/or metformin (potential
confounders).
Results. After adjustment for age, sex and glucose metabolism status, one standard deviation increase in the ED Z score
was associated with a 1.9 [95% confidence interval (CI) 0.7–3.1] higher CES-D score. Additional adjustments did not
materially change this result. LGI and OxS were not associated with the CES-D score.
Conclusions. ED, as quantified by an array of circulating biomarkers and FMD, was independently associated with
depressive symptoms. This study supports the hypothesis that ED plays an important role in the pathobiology of
depression.
Received 23 August 2012; Revised 11 July 2013; Accepted 21 July 2013; First published online 13 August 2013
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Introduction
The pathobiology of depression is complex. It has
been suggested that endothelial dysfunction (ED), low-
grade inflammation (LGI) and oxidative stress (OxS)
are involved, as these phenomena may interfere with
neurotransmitter metabolism, the hypothalamic–
pituitary–adrenal (HPA) axis and the homeostatic pro-
cess of neurogenesis in the brain (Belmaker & Agam,
2008; Dantzer et al. 2008; Miller et al. 2009; Krishnan
& Nestler, 2010). However, these observations derive
primarily from studies in animals. In humans, the
study of these phenomena in the pathobiology of de-
pression is more complicated. One approach is to
study ED, LGI and OxS through the determination of
biomarkers in peripheral blood, which assumes that
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ED, LGI and OxS are generalized phenomena and that
each of these phenomena represents ED, LGI or OxS
either directly or indirectly in the brain.
The concepts of ED (Aird, 2007a,b), LGI (Miller et al.
2009) and OxS (Maes et al. 2011) are heterogeneous in
nature. These concepts can be defined individually in
many different ways without it being clear that one
definition necessarily favours the other in relation to
depression. For example, ED has been defined as bra-
chial artery impaired flow-mediation (Sherwood et al.
2005), but also by an increased level of circulating bio-
markers [e.g. soluble vascular cell adhesion molecule 1
(sVCAM-1), soluble endothelial selectin (sE-selectin),
soluble thrombomodulin (sTM)] (Do et al. 2010;
Thomas et al. 2007). In addition, many different circu-
lating biomarkers have been used to assess LGI [e.g.
C-reactive protein (CRP), interleukin 6 (IL-6) and
IL-1, and tumour necrosis factor-α (TNF-α)] (Tiemeier
et al. 2003; Howren et al. 2009) and OxS [e.g. myeloper-
oxidase (MPO) and oxidized low density lipoprotein
(oxLDL)] (Kupper et al. 2009; Maes et al. 2010). Fur-
thermore, some studies have used a single biomarker
to define the concepts of ED/LGI/OxS (Lesperance
et al. 2004; Sherwood et al. 2005) whereas others have
used multiple markers (Tiemeier et al. 2003; Do et al.
2010). The different definitions of the concepts of
ED/LGI/OxS are exemplified by the fact that studies
on the association between biomarkers of ED (Thomas
et al. 2007; Pizzi et al. 2008), LGI (Tiemeier et al.
2003; Lesperance et al. 2004) and/or OxS (Forlenza &
Miller, 2006; Kupper et al. 2009) and depression have
yielded inconsistent results (Ford & Erlinger, 2004;
Panagiotakos et al. 2004; Empana et al. 2005; Sherwood
et al. 2005; Rybakowski et al. 2006; Narita et al. 2007;
Elovainio et al. 2009; Schott et al. 2009; Cooper et al.
2010; Do et al. 2010; Maes et al. 2010; Paranthaman
et al. 2010). In addition, these inconsistent results
may be explained by the manner in which biomarkers
of ED, LGI and/or OxS were determined (e.g. differ-
ent laboratory techniques), the manner in which
depression was assessed (e.g. interview versus ques-
tionnaire) and the populations investigated (e.g.
clinical- versus population-based studies).
Nevertheless, and taken together, many studies
(Tiemeier et al. 2003; Ford & Erlinger, 2004;
Lesperance et al. 2004; Panagiotakos et al. 2004;
Elovainio et al. 2009; Howren et al. 2009) have found
a positive association between LGI and depression,
particularly for the LGI biomarkers CRP and the inter-
leukins IL-6 and IL-1, most notably in clinical-based
sampled studies and in studies in which depression
was assessed by interview (Howren et al. 2009). For
ED the evidence is less clear. In relatively small
and/or selected populations (Sherwood et al. 2005;
Rybakowski et al. 2006; Narita et al. 2007; Pizzi et al.
2008; Cooper et al. 2010) in particular, flow-mediated
dilatation (FMD) was associated with depression to
such an extent that a smaller FMD response was as-
sociated with more severe depressive symptoms.
With regard to OxS, no clear picture emerges.
Previous studies (Forlenza & Miller, 2006; Kupper
et al. 2009; Maes et al. 2011) have defined OxS in
many different ways and have yielded contradictory
results. Importantly, most of these studies examined
ED, LGI and OxS in isolation whereas these processes
are biologically inter-related and may therefore be
interdependent (Stehouwer et al. 2002).
In view of these considerations, we investigated com-
prehensively, in a population-based study, the relation-
ship between ED, LGI and OxS on the one hand
and depressive symptoms on the other. In addition,
we investigated whether any such associations were
independent of diabetes, prior cardiovascular disease
(CVD), physical activity, dietary habits and socio-
economic status. Finally, we investigated whether ED,
LGI and OxS were associated with depressive symp-
toms independently of each other.
Method
Study design
For the current study, we used cross-sectional data
from the 2000 Hoorn Study. The Hoorn Study, which
started in 1989, is a population-based cohort study
of glucose metabolism in relation to CVD risk factors
(Mooy et al. 1995; Spijkerman et al. 2002; Henry
et al. 2003). In brief, 2484 men and women, aged
50–75 years, from the population register of the
medium-sized Dutch town of Hoorn participated in
the baseline examination. In 1996–1998 (visit 2), 1513
(73%) of all surviving participants agreed to participate
in the first follow-up. In 2000 (visit 3), all of those who
were diagnosed as having diabetes during the pre-
vious examinations (n=176) and random samples of
individuals with normal glucose metabolism (n=705)
and impaired glucose metabolism (n=193) were
invited, of whom 648 (60%) participated. The local
ethics committee approved the study and all partici-
pants gave their written informed consent.
Depressive symptoms
Depressive symptoms were assessed by a validated
Dutch version of the 20-item Center for Epidemiologic
Studies Depression Scale (CES-D; Beekman et al. 1997).
Scores on the CES-D range from 0 to 60. Higher scores
on this scale indicate the presence of more (severe) de-
pressive symptoms. In the present study, the CES-D
was used both as a continuous and as a dichoto-
mous variable with a predefined cut-off level of 16
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(Beekman et al. 1997). The latter represents the pres-
ence of clinically relevant depressive symptoms.
ED, LGI and OxS
ED was assessed by FMD of the brachial artery accord-
ing to the guidelines of the International Brachial
Artery Reactivity Task Force (Corretti et al. 2002), as
described previously (Henry et al. 2004). In addition,
ED was assessed by the quantification of the following
circulating biomarkers: sVCAM-1, sE-selectin, sTM,
soluble intercellular adhesion molecule 1 (sICAM-1)
and von Willebrand factor (vWF). LGI was assessed
by the quantification of high-sensitivity CRP, serum
amyloid A (SAA), IL-6, IL-8, TNF-α, MPO and
sICAM-1. OxS was determined by the quantification
of oxLDL and MPO.
In brief, serum biomarkers of ED (sVCAM-1,
sE-selectin, sTM, sICAM-1) and LGI (CRP, SAA, IL-6,
IL-8, TNF-α) were assessed by a multi-array detection
system based on electrochemiluminescence technology
(SECTOR Imager 2400, Meso Scale Discovery, USA);
details have been described elsewhere (van Bussel
et al. 2011a). In addition, vWF was determined in
citrated plasma by means of an enzyme-linked immu-
nosorbent assay (ELISA) (van Bussel et al. 2011a),
plasma oxLDL by competitive ELISA (Mercodia,
Sweden) (van der Zwan et al. 2009) and MPO in ethyl-
enediaminetetraacetic acid (EDTA) plasma by a sand-
wich ELISA (Mercodia) (Van der Zwan et al. 2010a).
In our laboratory, intra- and inter-assay coefficients
of variation (CVs) were respectively: 2.8% and 5.6%
for sVCAM-1, 2.6% and 6.7% for sE-selectin, 2.1% and
6.9% for sTM, 2.4% and 4.9% for sICAM-1, 2.8%
and 4.0% for CRP, 2.7% and 11.6% for SAA, 5.6%
and 13.0% for IL-6, 5.6% and 12.2% for IL-8, and
3.9% and 8.8% for TNF-α. In addition, the intra- and
inter-assay CVs were respectively 3.4% and 7.9% for
vWF (van Bussel et al. 2011a), 6.7% and 7.0% for
oxLDL (van der Zwan et al. 2009) and 3.9% and 5.0%
for MPO (Van der Zwan et al. 2010a).
Other measurements
We determined medical history, education level, cur-
rent medication use, anthropometrical (body height,
weight, waist and hip circumference) and biological
[blood pressure, total, high density lipoprotein (HDL)
and LDL cholesterol, triglyceride and glucose levels,
creatinine, albuminuria] variables as described else-
where (Spijkerman et al. 2002; Henry et al. 2003). For
assessment of glucose status, all participants, except
those with previously diagnosed diabetes, underwent
a standard 75-g oral glucose tolerance test and were
classified as having normal glucose metabolism
(NGM), impaired glucose metabolism (IGM; impaired
fasting glucose and/or impaired glucose tolerance) or
type 2 diabetes according to the 1999 World Health
Organization criteria (Unwin et al. 2002). Smoking
habits were categorized as current, former and non-
smokers. Hypertension was defined as a systolic
blood pressure (BP) 5140 mmHg and/or diastolic BP
590 mmHg and/or the current use of antihypertensive
medication. Estimated glomerular filtration rate (eGFR
in ml/min/1.73m2) was calculated according to the
Modification of Diet in Renal Disease (MDRD) short
formula (without assay calibration): 186× (serum
creatinine)−1.154× (age)−0.203×1.212 (if black)×0.742 (if
female) (Levey et al. 2007). Education level was dichot-
omized as low (secondary school or less) versus higher
education. Physical activity, expressed as metabolic
equivalent of task (MET) h/week, was assessed by
the Short Questionnaire to Assess Health-Enhancing
Physical Activity (SQUASH; Wendel-Vos et al. 2003).
Diet was assessed by a validated self-administered
Food Frequency Questionnaire (FFQ; Ocke et al.
1997a,b; Du et al. 2008). In the FFQ, participants
were asked to report habitual diet over the previous
year (Ocke et al. 1997a,b). Based on the FFQ, we cal-
culated the alternative Mediterranean diet (aMED)
score as described by Fung et al. (2005). The aMED
score quantifies ‘diet quality’ and is based on the diet-
ary intake of vegetables, legumes, fruit, nuts, whole
grains, meat, fish, unsaturated and saturated fat and
ethanol.
Statistical analysis
All analyses were performed with PASW Statistics 18
(IBM, USA).
FMD was analysed as a functional marker of ED. For
descriptive purposes, FMD values were reversed, that
is multiplied by −1 (higher values indicating worse
endothelial function), and an FMD Z score was cal-
culated according to the formula: (individual value –
population mean)/[population standard deviation
(S.D.)]. In all statistical analyses, the FMD Z score was
adjusted for baseline diameter, flow increase after
cuff release and nitroglycerin-mediated dilatation
(NMD).
For reasons of statistical efficiency and to reduce the
influence of the biological variability of each measure,
a circulating biomarker Z score was determined for the
individual circulating biomarkers of ED, LGI and OxS
according to predefined clusters of conceptually rel-
ated biomarkers (Jager et al. 1999; Yudkin et al. 1999;
van Bussel et al. 2011b). The circulating biomarker
Z scores were calculated as follows: for each individual
circulating biomarker, a Z score was calculated. The
resulting Z scores were then averaged into the circulat-
ing biomarker Z score for ED, LGI and OxS. The ED
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circulating biomarker Z score consisted of scores for
sVCAM-1, sE-selectin, sTM, sICAM-1 and vWF. In
addition, we combined the FMD Z score and the ED
circulating biomarker Z score into a ‘total ED’ score.
The LGI circulating biomarker Z score consisted of
scores for CRP, SAA, IL-6, IL-8, TNF-α, MPO and
sICAM-1. As both monocytes and the endothelium ex-
press sICAM-1 (Schram & Stehouwer, 2005), sICAM-1
was included in the Z score of both LGI and ED.
The OxS circulating biomarker Z score consisted of
oxLDL and MPO. As MPO is a measure of both oxi-
dative stress and inflammation (Schindhelm et al.
2009), it was included in the Z score of OxS and LGI.
Linear and logistic regression analyses were used to
evaluate the associations between, on the one hand,
the total ED score, the FMD Z score and the circu-
lating biomarker Z scores of ED, LGI and OxS and,
on the other, depressive symptoms (CES-D score; the
analyses were performed for both the continuous
and the dichotomous CES-D score). We first adjusted,
in all models, for the stratification variables of the
Hoorn Study cohort: age, sex and glucose metabolism
status (model 1). These associations were then ad-
ditionally adjusted for the following sets of potential
confounders (Panagiotakos et al. 2004; Empana et al.
2005; Pizzi et al. 2008): conventional CVD risk factors
[prior CVD, hypertension, waist-to-hip ratio (WHR),
triglycerides and total/HDL cholesterol (model 2)], life-
style factors [education level, physical activity, smok-
ing status and aMED score (model 3)] and the use of
antihypertensive and/or lipid-lowering medication
and/or metformin (model 4). In models 5–7, mutual
adjustments were made for each of the individual
Z scores.
The association between ED, LGI or OxS and
depression might be different according to sex (Ford
& Erlinger, 2004; Krishnan & Nestler, 2010) or glucose
metabolism status (Musselman et al. 2003). For in-
stance, the hyperglycaemic state may amplify the effect
of ED, LGI and/or OxS on depressive symptoms/
depression, even though the hyperglycaemic state
itself enhances these processes. In addition, some
studies have shown an association between LGI in
men but not in women (Penninx et al. 2003; Ford &
Erlinger, 2004); this may be due to the effect of gonadal
hormones on the level of plasma biomarkers (Ford &
Erlinger, 2004). To investigate these possible inter-
actions, we added to our models interaction terms
between sex and ED/LGI/OxS and between glucose
metabolism status and ED/LGI/OxS.
A p value < 0.05 was considered statistically signifi-
cant, except for the interaction analyses, where p values
< 0.10 were used. Interaction analyses are handicapped
in that they compare smaller subsets of study subjects
and therefore have less power than the primary study
analysis (Rothman et al. 2008). The use of a higher
p value is recommended (Selvin, 1996) to enable the
detection of any potentially important interaction,
even though such a greater p value enhances the possi-
bility of a type 1 error.
Results
Participants
Of the 648 participants, 84 had missing CES-D data
and 14 had incomplete glucose data. In the remaining
550 participants, full data on circulating biomarkers of
ED, LGI and OxS were available in 493 participants
(study population), of whom 357 had FMD measure-
ments of sufficient quality (i.e. clear visual definition
of the arterial wall throughout the entire measurement;
Henry et al. 2004). Participants with missing biomarker
data were older (72 v. 69 years) and more often had
type 2 diabetes (40% v. 20%; p for all <0.05). Par-
ticipants with missing FMD data were older (72 v.
68 years), more often had type 2 diabetes (35% v.
17%) and had a higher CES-D score (9 v. 6; p for all
<0.05). In addition, these participants had a worse
CVD risk factor pattern (data not shown).
Clinical characteristics
Tables 1 and 2 show the characteristics of the study
population according to the presence of clinically rel-
evant depressive symptoms (i.e. CES-D score 516).
According to the CES-D cut-off level, 63 participants
(12.8%) had clinically relevant depressive symptoms.
In persons with clinically relevant depressive symp-
toms compared to those without, the total ED score,
the FMD Z score and the circulating biomarker
Z scores of ED, LGI and OxS were higher.
Association between ED, LGI and OxS and
depressive symptoms
The results of the linear regression analyses (CES-D
expressed on a continuous scale) show that, after ad-
justment for age, sex and glucose metabolism status,
1 s.D. increase in the total ED score was associated
with a higher CES-D score with a regression coefficient
of 1.9 [95% confidence interval (CI) 0.7–3.1] (Table 3,
model 1; also illustrated in Fig. 1a). The LGI and
OxS circulating biomarker Z scores were not signifi-
cantly associated with a higher CES-D score [re-
gression coefficients 0.4 (95% CI −0.6 to 1.5) and 0.7
(95% CI −0.1 to 1.5) respectively] (Table 3, model 1,
and Fig. 1a). Further adjustments for prior CVD,
hypertension, WHR, total/HDL cholesterol, triglycer-
ides, educational level, physical activity, smoking,
aMED score and the use of antihypertensive and
1406 T. T. van Sloten et al.
https://doi.org/10.1017/S0033291713002043
Downloaded from https://www.cambridge.org/core. Universiteit Maastricht, on 16 Sep 2021 at 07:17:51, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
lipid-lowering medication, and metformin did not
materially alter these results (models 2–4). Further-
more, the associations for the total ED score and the
OxS circulating biomarker Z score did not materially
change if model 1 was additionally adjusted for each
of the other biomarkers scores (models 5–7). When
we adjusted the LGI circulating biomarker Z score
for the ED circulating biomarker Z score, the regression
coefficient changed from 0.4 (95% CI −0.6 to 1.5) to
−0.1 (95% CI −1.2 to 1.1) (model 7). This change in
the point estimate should nevertheless be interpreted
with caution, as the CI of both point estimates incor-
porates the value zero.
Association between ED, LGI and OxS and clinically
important depressive symptoms
The results of the logistic regression analyses (CES-D
expressed on a dichotomous scale) show that, after
adjustment for age, sex and glucose metabolism status,
a 1 s.D. increase in the total ED score was associated
with clinically important depressive symptoms with
an odds ratio (OR) of 1.9 (95% CI 0.9–3.8) (Table 4,
model 1). The LGI and OxS circulating biomarker
Z scores were associated with clinically important
depressive symptoms with an OR of 1.3 (95% CI
0.8–2.0) and 1.2 (95% CI 0.8–1.8) respectively










Former smoker 63.2 49.2
Current smoker 15.9 14.3
Low education level 21.4 36.5
Physical activity (MET h/week) 80 (47–130) 56 (25–104)
aMED score 4.0 (3.0–5.0) 4.0 (3.0–5.0)
Glucose metabolism status
Normal glucose metabolism 49.8 30.2
Impaired glucose metabolism 31.6 38.1
Type 2 diabetes mellitus 18.6 30.1
Prior cardiovascular disease 46.3 52.5
Metabolic variables
Body mass index (kg/m2) 26.6 (24.5–29.3) 28.9 (25.3–31.4)
Waist-to-hip ratio 0.93 (0.86–0.99) 0.94 (0.86–0.99)
Systolic blood pressure (mmHg) 142 (127–156) 144 (130–159)
Diastolic blood pressure (mmHg) 83 (76–90) 83 (72–92)
Hypertension 67.9 71.4
HbA1c (mmol/mol) 39.9 (37.7–44.3) 41.0 (37.7–47.0)
HbA1c (%) 5.8 (5.6–6.2) 5.9 (5.6–6.5)
Total cholesterol (mmol/l) 5.7 (5.0–6.3) 6.0 (4.9–6.7)
LDL cholesterol (mmol/l) 3.6 (3.0–4.2) 3.8 (2.9–4.4)
HDL cholesterol (mmol/l) 1.4 (1.1–1.7) 1.3 (1.0–1.5)
Triglycerides (mmol/l) 1.3 (1.0–1.7) 1.4 (1.2–2.1)
Albuminuria (albumin/creatinine ratio>2mg/mmol) 14.7 9.5
eGFR (ml/min/1.73m2) 77.4 (70.0–89.5) 76 (64.8–89.7)
Medication
Lipid-lowering medication 15.6 17.5
Antihypertensive medication 64.6 44.4
Antidepressive medication 1.9 3.2
CES-D, Center for Epidemiologic Studies Depression Scale; MET, metabolic equivalent of task; aMED, alternative
Mediterranean diet; HbA1c, glycosylated haemoglobin; LDL, low density lipoprotein; HDL, high density lipoprotein; eGFR,
estimated glomerular filtration rate.
Data are presented as percentage or median (interquartile range).
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(Table 4, model 1). Further adjustments for prior CVD,
hypertension, WHR, total/HDL cholesterol, triglycer-
ides, educational level, physical activity, smoking,
aMED score and the use of antihypertensive and
lipid-lowering medication, and metformin did not
materially change these results (models 2–4). If we
adjusted the total ED score for the LGI circulating bio-
marker Z score, the OR changed from 1.9 (95% CI
0.9–3.8) to 2.4 (95% CI 1.1–5.4) (model 5). If we
adjusted the results of the LGI and OxS circulating bio-
marker Z scores for each of the other biomarker scores,
the results did not materially change (models 5–7).
Additional analyses
Analyses of the associations between the individual
elements of the ED, LGI and OxS circulating biomarker
Z scores and the CES-D score on a continuous
scale show that all individual circulating biomarkers,
except sE-selectin and MPO, were associated with the
CES-D score (statistically significant for sVCAM-1,
vWF and oxLDL; see Fig. 1b–d). Previous studies
(Ridker et al. 2000; Brevetti et al. 2001) have suggested
that sICAM-1 may be a marker of both ED and LGI.
When the analyses were repeated with sICAM-1 left
out of either the ED or the LGI circulating biomarker
Z score, the results did not materially change (data
not shown). In addition, we considered MPO as a mar-
ker of both LGI and OxS (Brennan et al. 2003; van der
Zwan et al. 2010b). When the analyses were repeated
leaving MPO out of the LGI circulating biomarker
Z score, the results did not materially change (data
not shown). Finally, it is unclear whether a high or a
Table 2. Markers of endothelial dysfunction (ED), low-grade inflammation (LGI) and oxidative stress (OxS) according to the presence of






Total ED score (S.D.) −0.09 (−0.42 to 0.29) 0.15 (−0.19 to 0.45)
FMD Z score (S.D.) 0.09 (−0.56 to 0.71) 0.50 (−0.18 to 0.91)
Absolute change in diameter (mm) 0.17 (0.08 to 0.27) 0.10 (0.04 to 0.21)
Percentage change in diameter 3.7 (1.5 to 5.9) 2.5 (0.7 to 4.8)
Baseline diameter (mm) 4.62 (4.13 to 5.08) 4.59 (3.97 to 4.89)
Flow increase after cuff release (%) 82 (58 to 107) 91 (56 to 118)
NMD (mm) 0.42 (0.30 to 0.56) 0.39 (0.27 to 0.52)
ED circulating biomarker Z score (S.D.) −0.15 (−0.44 to 0.30) 0.04 (−0.32 to 0.52)
sVCAM-1 (μg/l) 390.6 (342.3 to 446.4) 427 (350.4 to 486.1)
sE-selectin (μg/l) 17.9 (13.9 to 23.4) 16.6 (12.2 to 21.3)
sTM (μg/l) 3.4 (2.9 to 4.0) 3.5 (3.1 to 4.1)
sICAM-1 (μg/l) 248.8 (219.0 to 286.3) 257.9 (223.9 to 294.4)
vWF (%) 146.5 (114.9 to 180.0) 177.4 (135.2 to 212.0)
LGI
LGI circulating biomarker Z score (S.D.) −0.08 (−0.43 to 0.26) 0.10 (−0.34 to 0.41)
CRP (mg/l) 2.2 (1.2 to 4.6) 2.7 (1.2 to 5.0)
SAA (mg/l) 1.7 (1.0 to 3.2) 2.0 (1.4 to 3.0)
IL-6 (ng/l) 1.5 (1.1 to 2.4) 1.8 (1.2 to 2.6)
IL-8 (ng/l) 15.0 (11.5 to 19.6) 15.5 (12.2 to 19.6)
TNF-α (ng/l) 8.4 (7.1 to 10.0) 8.9 (7.8 to 10.3)
MPO (μg/l) 55.2 (46.9 to 65.2) 57.3 (48.8 to 67.6)
sICAM-1 (μg/l) 248.8 (219.0 to 286.3) 257.9 (223.9 to 294.4)
OxS
OxS circulating biomarker Z score (S.D.) −0.06 (−0.48 to 0.37) 0.18 (−0.46 to 0.64)
oxLDL (U/l) 62.1 (53.7 to 73.1) 66.6 (53.3 to 80.8)
MPO (μg/l) 55.2 (46.9 to 65.2) 57.3 (48.8 to 67.6)
CES-D, Center for Epidemiologic Studies Depression Scale; FMD, flow-mediated dilatation; NMD, nitroglycerin-mediated
dilatation; sVCAM-1, soluble vascular adhesion molecule 1; sE-selectin, soluble endothelial selectin; sTM, soluble thrombo-
modulin; sICAM-1, soluble intracellular adhesion molecule 1; vWF, von Willebrand factor; CRP, C-reactive protein;
SAA, serum amyloid A; IL-6, interleukin 6; IL-8, interleukin 8; TNF-α, tumour necrosis factor α; MPO, myeloperoxidase;
oxLDL, oxidized low density lipoprotein; S.D., standard deviation.
Data are presented as medians (interquartile range).
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Table 3. Associations of endothelial dysfunction (ED), low-grade inflammation (LGI) and oxidative stress (OxS) with depressive symptoms (continuous CES-D score)
ED LGI OxS







1 Age, sex, glucose metabolism status 1.9 (0.7–3.1) 0.7 (0.1 to 1.4) 1.3 (0.2 to 2.5) 0.4 (−0.6 to 1.5) 0.7 (−0.1 to 1.5)
2 Model 1+prior CVD, hypertension, WHR,
triglycerides, total/HDL cholesterol
1.8 (0.6–3.0) 0.7 (0.05 to 1.3) 1.0 (0.1 to 1.9) 0.3 (−0.8 to 1.3) 0.6 (−0.3 to 1.4)b
3 Model 1+education level, physical activity,
smoking status, aMED score
1.8 (0.6–3.0) 0.6 (−0.01 to 1.3) 1.1 (0.2 to 2.1) 0.3 (−0.8 to 1.3) 0.6 (−0.2 to 1.4)
4 Model 1+antihypertensive and lipid-lowering
medication, metformin
1.9 (0.7–3.1) 0.7 (0.1 to 1.4) 1.3 (0.2 to 2.5) 0.4 (−0.6 to 1.5) 0.7 (−0.2 to 1.5)
5 Model 1+LGI Z score 2.1 (0.9–3.3) 0.7 (0.1 to 1.4) 1.3 (0.2 to 2.3) – 0.6 (−0.2 to 1.5)
6 Model 1+OxS Z score 1.9 (0.7–3.1) 0.7 (0.1 to 1.3) 1.2 (−0.1 to 2.4) 0.2 (−0.8 to 1.2) –
7 Model 1+ED Z score – – – −0.1 (−1.2 to 1.1) 0.4 (−0.4 to 1.3)
CES-D, Center for Epidemiologic Studies Depression Scale; FMD, flow-mediated dilatation; CVD, cardiovascular disease; WHR, waist-to-hip ratio; HDL, high density lipoprotein;
aMED, alternative Mediterranean diet.
Values are given as regression coefficients (95% confidence interval) expressed per standard deviation increase in total ED score (n=357), FMD Z score (n=357), ED circulating bio-
marker Z score (n=493), LGI circulating biomarker Z score (n=493) and (OxS) circulating biomarker Z score (n=493) on the CES-D.
a The FMD Z score was reversed, that is multiplied by −1; higher values indicating worse endothelial function. In all analyses the FMD Z score was adjusted for baseline diameter,
flow increase after cuff release and nitroglycerin-mediated dilatation (NMD).
b The OxS circulating biomarker Z score was not adjusted for triglycerides and total/HDL cholesterol as this was considered an overadjustment, as oxidized low density lipoprotein
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low concentration of sTM reflects ED (Wu, 2003).
The results did not materially change when we per-
formed the analysis with either the reversed value of
sTM or leaving sTM out of the total ED score (data
not shown).
To determine whether the association between FMD
and depression was due to impaired ED or smooth
muscle cell function (Henry et al. 2004), we repeated
the analyses with endothelium-independent NMD as
the primary determinant. These analyses showed that
NMD was not associated with (clinically relevant) de-
pressive symptoms (data not shown).
The associations between ED, LGI and OxS on
the one hand and depressive symptoms on the other
may differ according to sex or glucose metabolism
status (Musselman et al. 2003; Krishnan & Nestler,
2010). Overall, we found no such interactions (p inter-
action >0.10), except that stratified analysis showed
a stronger association between the LGI biomarker
Z score and depressive symptoms in persons with
impaired glucose metabolism compared to persons with
normal glucose metabolism (p interaction=0.03). In ad-
dition, the association between the OxS biomarker
Z score and depressive symptoms was stronger in per-
sons with impaired glucose metabolism (p interaction=
0.01) and in persons with type 2 diabetes (p interaction
=0.07), compared to persons with normal glucose metab-
olism (data not shown).
When the statistical analyses were repeated on
those participants (n=357) who had full data on both
circulating biomarkers and FMD, the results did not
materially change (data not shown). Finally, when
we repeated the analyses with clinically relevant de-
pressive symptoms defined as a CES-D score 516
and/or medication use for a depressive disorder (n=
67, 13.6%) as the outcome variable instead of clinically
relevant depressive symptoms only (CES-D 516), the
results did not materially change (data not shown).
-3 -2 -1 0 1 2 3
OxS circ. biomarker Z-score
LGI circ. biomarker Z-score




Regression coefficient (95% CI)
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Lower HigherCES-D score
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Fig. 1. Associations of endothelial dysfunction (ED), low-grade inflammation (LGI) and oxidative stress (OxS) with depressive
symptoms [continuous Center for Epidemiologic Studies Depression Scale (CES-D) score]. (a) Regression coefficients [95%
confidence intervals (CIs)] expressed per standard deviation (S.D.) increase in total ED score, flow-mediated dilatation (FMD)
Z score and ED, LGI and OxS circulating biomarker Z scores. The FMD Z score was reversed, that is multiplied by −1,
higher values indicating worse function. Also shown are individual circulating biomarkers (per S.D.) of (b) ED, (c) LGI and
(d ) OxS. All results are adjusted for age, sex and glucose metabolism status. sVCAM-1, Soluble vascular cell adhesion
molecule 1; sE-selectin, soluble endothelial selectin; sTM, soluble thrombomodulin; sICAM-1, soluble intercellular adhesion
molecule 1; vWF, von Willebrand factor; CRP, C-reactive protein; SAA, serum amyloid A; IL-6, interleukin 6; IL-8, interleukin
8; TNF-α, tumour necrosis factor α; MPO, myeloperoxidase; oxLDL, oxidized low density lipoprotein.
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Table 4. Associations of endothelial dysfunction (ED), low-grade inflammation (LGI) and oxidative stress (OxS) with clinically relevant depression (CES-D 516)
ED LGI OxS







1 Age, sex, glucose metabolism status 1.9 (0.9–3.8) 1.4 (0.9–2.4) 1.6 (1.0–2.3) 1.3 (0.8–2.0) 1.2 (0.8–1.8)
2 Model 1+prior CVD, hypertension, WHR,
triglycerides, total/HDL cholesterol
1.8 (0.9–3.7) 1.5 (0.9–2.5) 1.5 (1.0–2.3) 1.3 (0.8–2.0) 1.2 (0.8–1.7)b
3 Model 1+education level, physical activity,
smoking status, aMED score
2.1 (1.0–4.1) 1.5 (0.9–2.5) 1.7 (1.1–2.5) 1.3 (0.8–2.1) 1.2 (0.8–1.8)
4 Model 1+antihypertensive and lipid-lowering
medication, metformin
2.0 (1.0–4.0) 1.5 (0.9–2.5) 1.6 (1.1–2.4) 1.3 (0.8–2.0) 1.2 (0.8–1.8)
5 Model 1+LGI Z score 2.4 (1.1–5.4) 1.4 (0.9–2.4) 1.6 (1.0–2.4) – 1.2 (0.8–1.8)
6 Model 1+OxS Z score 2.0 (1.0–4.2) 1.4 (0.9–2.4) 1.5 (1.0–2.3) 1.3 (0.8–2.0) –
7 Model 1+ED Z score – – 1.0 (0.6–1.7) 1.1 (0.7–1.7)
CES-D, Center for Epidemiologic Studies Depression Scale; FMD, flow-mediated dilatation; CVD, cardiovascular disease; WHR, waist-to-hip ratio; HDL, high density lipoprotein;
aMED, alternative Mediterranean diet.
Values are given as odds ratios (95% confidence interval) expressed per standard deviation increase in total ED score (n=357), FMD Z score (n=357), ED circulating biomarker Z
score (n=493), LGI circulating biomarker Z score (n=493) and OxS circulating biomarker Z score (n=493). Sixty-three (12.8%) of the study participants had clinically relevant depress-
ive symptoms (CES-D score 516).
a The FMD Z score was reversed, that is multiplied by −1, higher values indicating worse endothelial function. In all analyses the FMD Z score was adjusted for baseline diameter,
flow increase after cuff release and nitroglycerin-mediated dilatation (NMD).
b The OxS circulating biomarker Z score was not adjusted for triglycerides and total/HDL cholesterol as this was considered an overadjustment, as oxidized low density lipoprotein
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The present investigation is the first population-based
study that simultaneously assessed the association of
ED, LGI and OxS with depressive symptoms in one
study. The study had three main findings. First,
ED, as quantified by FMD and circulating biomarkers,
was associated with a higher level of (clinically rel-
evant) depressive symptoms. This association was
independent of age, sex, diabetes, CVD risk factors,
physical activity, dietary intake and education level.
Second, circulating biomarkers for LGI and OxS were
not statistically significantly associated with depressive
symptoms. Third, adjustments for LGI or OxS did
not affect the association between ED and depressive
symptoms, which suggests that ED is associated with
depressive symptoms/depression, independently of
LGI and OxS.
A key concept underlying this study is that ED,
LGI and OxS are generalized phenomena and that
each of these phenomena represents either directly or
indirectly ED, LGI or OxS in the brain. Currently, lit-
erature on this topic is limited. Nevertheless, it can
be hypothesized that the impaired cerebral circulatory
function seen in depression, as determined by trans-
cranial Doppler ultrasonography (Direk et al. 2012),
may be the consequence of decreased endothelium-
dependent vasodilation. In addition, it has been shown
that the process of neurogenesis (i.e. the process by
which neural progenitors divide and form new neur-
ons and neuronal networks) is disturbed in depression
(Belmaker & Agam, 2008; Krishnan & Nestler, 2010)
and that this disturbance may, at least partially, be
the consequence of ED (Shen et al. 2004; Zhao et al.
2008).
On aggregate, most studies thus far (Lesperance
et al. 2004; Empana et al. 2005; Sherwood et al.
2005; Rybakowski et al. 2006; Narita et al. 2007; Pizzi
et al. 2008; Schott et al. 2009; Cooper et al. 2010;
Paranthaman et al. 2010) have shown that ED and
depression seem to be associated. However, conflicting
results in the literature do exist. For instance, Thomas
et al. (2007) did not observe any association between
ED and depression in a small and select population
of patients diagnosed with major depressive disorder.
In their study, however, it is unclear how potential
confounders were taken into account (e.g. anti-
inflammatory medication). An alternative explanation
for the reported heterogeneous results may lie in the
fact that endothelial function can be defined in many
ways as its functions are multi-dimensional and
heterogeneous (Aird, 2007a,b). This is exemplified by
Paranthaman et al. (2010) who did report an associ-
ation between ED and depression but quantified
ED as the vasodilatory response to acetylcholine of
biopsied small gluteal arteries. Do et al. (2010) quan-
tified ED by multiple circulating biomarkers and re-
ported an association between ED and, specifically,
hopelessness, which reflects, as argued by the authors,
a distinct and unique component of depression only.
Pizzi et al. (2008) quantified ED by FMD and showed
an association between FMD and depressive symp-
toms; however, in their study no adjustments were
made for important confounders, such as physical
activity and dietary habits.
The present investigation extends previous obser-
vations because of its population-based design, the
extensive assessment of ED, LGI and OxS, and the de-
tailed clinical characterization of its participants,
which enabled us to adjust for a series of potential
confounders.
Apart from a causal association between ED and de-
pression, other underlying mechanisms might explain
the observed association. First, ED is involved in the
pathophysiology of CVD (Aird, 2007a,b) and de-
pression is common in persons with CVD (Belmaker
& Agam, 2008). Therefore, it is possible that ED
might lead to depression through the development of
CVD. However, the association of ED with depressive
symptoms remained after adjustment for prior CVD
and several CVD risk factors. Second, depressive
symptoms by themselves might initiate or promote
ED (reverse causality), as depressive symptoms/de-
pression are associated with unfavourable lifestyle
habits, such as physical inactivity, unhealthy dietary
habits, smoking and obesity, which are by themselves
associated with ED. The association between ED and
depressive symptoms, however, remained after adjust-
ment for unfavourable lifestyle habits. Third, other
mechanisms may underlie both ED and depression.
For instance, abnormal HPA axis function (Broadley
et al. 2006) and deficits in omega-3 fatty acids (Parker
et al. 2006) have been associated with both ED and de-
pression. In the current study, cortisol and omega-3
fatty acids levels were not available and this issue
needs further study. Fourth, ED, LGI and OxS are,
from a biological point of view, closely linked and
these concepts are difficult to separate (Stehouwer
et al. 2002). Therefore, any association of ED with de-
pressive symptoms may be confounded by LGI and/
or OxS. However, when we adjusted the association
between ED and depression for LGI or OxS, ED and
depression remained associated. This suggests that
ED may affect the brain through a pathway indepen-
dent of LGI and OxS. For instance, it might be possible
that ED directly affects the process of neurogenesis
(Shen et al. 2004; Zhao et al. 2008), or ED might directly
impair cerebral circulatory function (Lemke et al. 2010).
In our study, the LGI and the OxS Z scores were as-
sociated with clinically relevant depressive symptoms,
1412 T. T. van Sloten et al.
https://doi.org/10.1017/S0033291713002043
Downloaded from https://www.cambridge.org/core. Universiteit Maastricht, on 16 Sep 2021 at 07:17:51, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
with effect sizes comparable to the results reported in
the literature (Ford & Erlinger, 2004; Lesperance et al.
2004; Panagiotakos et al. 2004; Empana et al. 2005;
Forlenza & Miller, 2006; Miller et al. 2009). However,
in our study these associations did not reach statistical
significance. We cannot exclude the possibility that this
may be due to a lack of statistical power. Indeed, a
meta-analysis by Howren et al. (2009) did show a sig-
nificant association between different markers of LGI
(CRP, IL-1 and IL-6) and depression/depressive symp-
toms. With regard to OxS in particular, we only as-
sessed two biomarkers (MPO and oxLDL); there is
also an ongoing debate how OxS could best be defined.
We explored whether the relationship between ED,
LGI and OxS and depression differed according to glu-
cose metabolism status. Our findings show that the
association between the LGI biomarker Z score and
depressive symptoms was stronger in persons with
impaired glucose metabolism than in those with
normal glucose metabolism. A plausible underlying
pathobiological explanation for this observation is
lacking. In addition, our results show that the associ-
ation between the OxS biomarker Z score and depress-
ive symptoms was stronger in persons with impaired
glucose metabolism and in those with type 2 diabetes.
We could speculate that the hyperglycaemic state
may indeed amplify the effect of OxS on depressive
symptoms/depression, even though the hypergly-
caemic state itself enhances OxS. Fully stratified ana-
lyses, however, were hampered by lack of power and
further studies of this issue are needed.
Our study has some limitations. First, the cross-
sectional design of our study precludes any con-
clusions about causality and it is possible that other
factors may explain the association between ED and
depressive symptoms/depression. Nevertheless, in
our study the association between ED and depressive
symptoms remained even after adjustment for glucose
metabolism status, CVD, obesity, physical inactivity,
poor dietary habits, smoking and education level.
Second, the construction of the Z scores assumes that
its components are equally important in the pathobio-
logy of depression, which is not necessarily true. This
might have caused us to underestimate the reported
associations. However, the use of the composite
Z score has the important merit of statistical efficiency.
Third, a relatively large number of statistical tests were
performed (we tested three ED scores and one each of
LGI and OxS); however, the associations between ED
and depressive symptoms were consistent across the
different ED scores. It is therefore unlikely that these
findings result by chance. Fourth, data were obtained
in an elderly white population and it therefore remains
to be established whether these results can be general-
ized to other populations.
In conclusion, the present population-based study
shows that ED, quantified by an array of peripherally
circulating biomarkers and FMD, is associated with
depressive symptoms. Our data thereby support the
hypothesis that ED plays an important role in the
pathobiology of depression.
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